Evidence map›Paper›PMID 27525197›Full record

ArticleExpert opinion on orphan drugs

Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin.

Adriana H Tremoulet, Sonia Jain, Jane C Burns

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on orphan drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Adjunctive therapies in Kawasaki disease.International journal of rheumatic diseases · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Adriana H TremouletKawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, California, USA; Rady Children's Hospital San Diego, San Diego, California, USA.
Sonia JainBiostatistics Research Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California.
Jane C BurnsKawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, California, USA; Rady Children's Hospital San Diego, San Diego, California, USA.
University of California, San Diego · USRady Children's Hospital-San Diego · US

Funding

Phase I and IIa trial of atorvastatin in children with acute Kawasaki diseaseR01HD081296 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREMOULET, ADRIANA H · 2014 to 2017
$1.3M
NICHD NIH HHS R01 HD081296
6 · The paper itself

Abstract

introductionSince the 1980s, the primary treatment of acute Kawasaki disease (KD) has been intravenous immunoglobulin and aspirin. However, 5-10% of children with acute KD will develop coronary artery abnormalities despite treatment within the first ten days after fever onset. There is no approved adjunctive therapy to prevent progression of coronary artery damage in these patients. AREAS COVERED: The rationale and study design of a Phase I/IIa trial of atorvastatin in children with acute KD and coronary artery inflammation is presented. The studies of host genetics and KD pathogenesis leading up to this trial are reviewed. EXPERT OPINION: The repurposing of well-studied drugs used in the adult population is a cost-effective and efficient strategy to identify new therapies for pediatric diseases. Exploiting the anti-inflammatory, non-lipid-lowering effects of statins may open up new applications for this class of drugs for the pediatric age group.

Indexed as

atorvastatinintravenous immunoglobulinKawasaki diseaserepurposing

Identifiers

PMID27525197
PMCPMC4979608
OpenAlexW2119214526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.